The Evidence Already Exists.
Most Tools Can't Reach It.
The evidence that could change a variant of unknown significance into a confident diagnosis, validate a new drug target, or identify eligible patients for a clinical trial… it already exists. It's published in the biomedical literature.
The problem is that it’s buried inside 18,000 journals, 39 million articles, and locked away in 4 million tables, appendices, and supplemental datasets that your current AI tools can’t access.
Missing that evidence has serious consequences: patients go undiagnosed, drug programs are built on incomplete assumptions, clinical trials don’t enroll eligible patients, and label expansions get left on the table, meaning fewer patients can access the right treatments after approval.
Built to Close the Evidence Gap.
Genomenon was founded in 2014 to solve the evidence gap because we understand the pressure you face as a clinician or program leader when you lack the required evidence needed to make a confident decision.
We harnessed the power of purpose-built AI, combined with expert scientific curation to index and structure real-world evidence from the full text, tables, and data from 11.2 million articles. We don’t just read the titles and abstracts.
The end-result is traceable and regulatory-grade evidence to support clinical diagnoses and drug development decisions at every stage of a product lifecycle.
Find the Evidence. Change the Outcome.
Today, more than 250 clinical diagnostic customers use Mastermind and Cancer Knowledgebase to interpret variants for germline or somatic diseases faster and with greater confidence.
More than 75 biopharmaceutical drug programs have used our customized real-world evidence to expand patient populations, optimize trial design, and support regulatory approvals.
We are based in Ann Arbor, Michigan. Our mission hasn't changed since day one: find the evidence that changes outcomes.
Labels expand. More patients reach the right treatment. Diagnoses get signed with confidence.
You shouldn’t have to make critical decisions with incomplete evidence. With Genomenon…You won’t.
Our Leadership Team
